Highlights Skye Bioscience, Inc.

Stocks

SKYE

US83086J2006

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 20:34:22 11/06/2026 +04			5-day change	1st Jan Change
0.8300 ^USD	+6.41%		+7.38%	+10.98%

05-20	Skye announces cohort review committee approved opening of cohort 2 based on favorable safety data from first four participants treated in cohort 1	RE
05-20	Skye Bioscience Announces Cohort Review Committee Approves Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1	CI

Highlights

05-20	Skye Bioscience Announces Cohort Review Committee Approves Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1	CI
05-12	Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-02	Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study	CI
03-11	Skye Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-02	Skye, Inc. Announces Interim Results from the Combination Cohort of the Company's Phase 2A Extension Study of Nimacimab	CI
11-11	Skye Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
06/10/25	Skye Bioscience Reports Topline Cbeyond?? Phase 2A Data from Nimacimab Monotherapy and Combination Clinical Trial	CI
19/09/25	Skye Bioscience, Inc. Presents Phase 1b Data for its Peripheral CB1-Inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes Annual Meeting	CI
04/09/25	Skye Bioscience, Inc.'s CB1 Inhibitor, Nimacimab Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-T Treatment Weight Maintenance in DIO Model	CI
02/09/25	Skye Bioscience, Inc. Completes 26-Week Treatment Phase in Phase 2a CBeyond Study	CI
08/08/25	Skye Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
23/06/25	Skye Bioscience Shares Nimacimab "Anatomy of Progress" Video Series and Highlights Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions	CI
13/05/25	Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral Cb1 Inhibition for Weight Loss Presented At European Congress on Obesity	CI
09/05/25	Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
15/04/25	Skye Bioscience, Inc. Announces New Preclinical Data for its Novel CB1 Antibody, Nimacimab	CI
21/03/25	Skye Bioscience Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Business Update	RE
21/03/25	Skye Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
21/03/25	Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
14/11/24	Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor	CI
08/11/24	Skye Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
04/11/24	Skye Bioscience Demonstrates Prominent Role of Peripheral Cb1 Inhibition and Achieves Significant Weight Loss with Novel Cb1-Inhibiting Antibody, Nimacimab, in Preclinical Model	CI
22/08/24	Skye Bioscience, Inc. Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated Cb1 Inhibitor, Nimacimab, in Patients with Obesity	CI
10/08/24	Skye Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24/07/24	Skye Bioscience, Inc. Announces Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints	CI
10/06/24	Skye Bioscience, Inc. Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program	CI